STOCK TITAN

COHBAR INC - CWBR STOCK NEWS

Welcome to our dedicated page for COHBAR news (Ticker: CWBR), a resource for investors and traders seeking the latest updates and insights on COHBAR stock.

CohBar Inc. (NASDAQ: CWBR) is a pioneering biotechnology company dedicated to transforming the way we approach chronic and age-related diseases. By harnessing the power of mitochondria through its innovative Mitochondria-Based Therapeutics (MBTs), the company is opening new frontiers in treating conditions that currently have limited or no treatment options.

CohBar's core business revolves around the discovery and development of therapeutic peptides encoded within the mitochondrial genome. These peptides, discovered by the company's founding scientists who are leaders in the fields of aging, metabolism, and mitochondrial genomics, have shown promise in addressing a wide array of diseases including type 2 diabetes, cancer, atherosclerosis, and neurodegenerative disorders.

Currently, CohBar is in the clinical-stage of development with several exciting projects in its pipeline. The company's most recent achievements include successful advancements in clinical trials and ongoing research into new peptide candidates. Financially, CohBar remains committed to maintaining a robust cash position to support its research and development activities.

Partnerships play a crucial role in CohBar's strategy. The company collaborates with leading academic institutions and other biotech firms to enhance its research capabilities and expedite the development of its therapeutic candidates.

Recent news highlights include the summary and financial results for the second quarter of 2023, showcasing CohBar's continuous progress and commitment to its mission. The company has also announced a proposed merger with Morphogenesis, which is expected to create significant synergies and enhance the combined entity's market presence.

For more detailed information about CohBar, its projects, and recent updates, visit their official website or follow them on LinkedIn. Investors are encouraged to contact the company directly at investors@cohbar.com for further inquiries.

Rhea-AI Summary

CohBar, Inc. (NASDAQ: CWBR) announced that CEO Steven Engle will participate in the 'Emerging Companies' panel at the Targeting Metabesity Conference from October 12-15, 2020. The panel discusses harnessing GeroScience to improve public health by preventing chronic diseases. Engle will present a corporate overview of CohBar's mitochondrial peptide technology on October 15 at 12:00 PM ET. Additionally, founder Dr. Nir Barzilai will speak on panels regarding metabesity diseases and the clinical translation of aging as a disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
conferences
-
Rhea-AI Summary

CohBar, Inc. (NASDAQ: CWBR), a biotechnology firm focused on mitochondria-based therapeutics, announced that CEO Steven Engle will present a company update at the BIO Investor Forum from October 13-15, 2020. The event is held virtually, and the presentation will be available on demand. CohBar is in Phase 1b of a clinical trial for its lead compound, CB4211, addressing NASH and obesity. The company has also developed several preclinical programs targeting various diseases linked to mitochondrial dysfunction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
conferences
-
Rhea-AI Summary

CohBar, a clinical stage biotechnology company, announced today that CEO Steven Engle will present an update at the H.C. Wainwright 4th Annual NASH Investor Conference. This virtual event is scheduled for October 5, 2020, at 12:00 PM ET. CohBar focuses on developing mitochondria-based therapeutics, with its lead compound CB4211 currently in a Phase 1b clinical trial targeting NASH and obesity. Furthermore, the company has four preclinical programs aimed at various chronic and age-related diseases, showcasing its commitment to addressing mitochondrial dysfunction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences
Rhea-AI Summary

CohBar, a clinical stage biotechnology company (NASDAQ: CWBR), will present an update at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 12:00 PM ET. CEO Steven Engle will discuss the company's focus on developing mitochondria-based therapeutics aimed at treating chronic diseases and enhancing healthy lifespan. CohBar's lead compound, CB4211, is in Phase 1b clinical trials for NASH and obesity, along with additional preclinical programs targeting various diseases. More information can be accessed via a webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences
-
Rhea-AI Summary

CohBar, a clinical stage biotechnology company focused on mitochondria-based therapeutics, announced that CEO Steven Engle will present an update at the Oppenheimer Fall Healthcare Summit on September 22, 2020, at 2:30 PM ET. The presentation will explore the company's advancements in developing therapies aimed at treating chronic diseases and extending healthy lifespans. CohBar's lead compound, CB4211, is in Phase 1b trials for NASH and obesity, with four additional preclinical programs targeting various diseases. For more details, access the presentation via webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
-
Rhea-AI Summary

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company, announced that CEO Steven Engle will present a company update at the H.C. Wainwright Annual Global Investment Conference, held virtually from September 14-16, 2020. Engle's presentation is scheduled for September 15 at 4:00 PM ET, which can be accessed via webcast. CohBar focuses on mitochondria-based therapeutics for chronic diseases, with its lead compound CB4211 in Phase 1b clinical trials for NASH and obesity, alongside four preclinical programs targeting various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
conferences
Rhea-AI Summary

CohBar, Inc. (NASDAQ: CWBR) has successfully closed its public offering of 12,300,000 units at $1.22 each, raising approximately $15.0 million. Each unit consists of one share of common stock and a warrant to purchase 0.75 shares at $1.44, with the underwriters partially exercising an over-allotment option for additional warrants. The offering is part of a shelf registration filed with the SEC. Funds from this offering are intended to support the development of CohBar’s mitochondria-based therapeutics, including its lead compound, CB4211, currently in a Phase 1b trial for NASH and obesity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
-
Rhea-AI Summary

CohBar, Inc. (NASDAQ: CWBR) announced a proposed underwritten public offering of units, which includes one share of common stock and a warrant to purchase 0.75 shares. Each warrant is exercisable for five years post-offering closure. The company plans to use net proceeds for general corporate purposes, including funding preclinical and clinical developments and increasing working capital. Roth Capital Partners is the sole book-running manager, with additional co-managers. The offering is subject to market conditions and no assurance can be given regarding its completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.64%
Tags
-
Rhea-AI Summary

CohBar, Inc. (NASDAQ: CWBR) announced the dosing of the first subjects in the Phase 1b clinical trial for CB4211, targeting NASH and obesity. Conducted on twenty obese participants with NAFLD, the study aims to evaluate the drug's effects on liver fat and body weight over four weeks. This is the first mitochondria-based therapeutic to enter clinical testing, with preclinical studies showing promise in regulating metabolism. CohBar anticipates topline data in Q1 2021, addressing a significant market need, with over 30 million patients affected by NASH in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
Rhea-AI Summary

CohBar, Inc. (CWBR) has reported preliminary positive results from its COVID-19 ARDS program, marking a significant advancement in its clinical research efforts. The company resumed its Phase 1b clinical study for treating NASH and obesity and raised $4.5 million from an at-the-market offering. Financial highlights for Q2 2020 include a net loss of $4.1 million and cash reserves of $12.3 million. CohBar also joined the Russell 2000 and 3000 Indexes, enhancing its market visibility. A conference call to discuss the results is scheduled for 5:00 p.m. ET on August 13, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.58%
Tags

FAQ

What is the current stock price of COHBAR (CWBR)?

The current stock price of COHBAR (CWBR) is $0.88 as of May 24, 2024.

What is the market cap of COHBAR (CWBR)?

The market cap of COHBAR (CWBR) is approximately 2.3M.

What does CohBar Inc. specialize in?

CohBar specializes in the research and development of Mitochondria-Based Therapeutics (MBTs) for treating chronic and age-related diseases.

What are Mitochondria-Based Therapeutics (MBTs)?

MBTs are a novel class of drugs derived from peptides encoded within the mitochondrial genome, aimed at treating diseases such as type 2 diabetes, cancer, and neurodegenerative disorders.

Who founded CohBar Inc.?

CohBar was founded by world-renowned scientists who are leaders in the fields of aging, metabolism, and mitochondrial genomics.

What recent achievements has CohBar made?

Recent achievements include advancements in clinical trials and ongoing research into new peptide candidates, as well as a proposed merger with Morphogenesis.

What diseases are targeted by CohBar’s therapies?

CohBar's therapies target a range of diseases including type 2 diabetes, cancer, atherosclerosis, and neurodegenerative disorders.

Is CohBar financially stable?

CohBar is committed to maintaining a robust cash position to support its research and development activities, ensuring financial stability.

How does CohBar collaborate with other entities?

CohBar collaborates with leading academic institutions and biotech firms to enhance its research capabilities and expedite the development of its therapeutic candidates.

What is the significance of the proposed merger with Morphogenesis?

The proposed merger with Morphogenesis is expected to create significant synergies and enhance the market presence of the combined entity.

How can investors get in touch with CohBar?

Investors can contact CohBar directly via email at investors@cohbar.com for further inquiries.

Where can I find more information about CohBar?

For more detailed information, visit CohBar’s official website or follow them on LinkedIn.

COHBAR INC

Nasdaq:CWBR

CWBR Rankings

CWBR Stock Data

2.33M
2.47M
15.09%
6.26%
0.5%
Biotechnology
Healthcare
Link
United States of America
Menlo Park